- Report
- September 2025
- 378 Pages
Global
From €5159EUR$5,850USD£4,466GBP
- Report
- August 2025
- 183 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 181 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 186 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- April 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- April 2025
- 250 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- April 2025
- 250 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- July 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- July 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- March 2025
- 250 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- March 2025
- 250 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- July 2025
Global
From €4321EUR$4,900USD£3,741GBP
- Report
- January 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- August 2025
- 195 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- April 2025
- 200 Pages
Global
From €7011EUR$7,950USD£6,070GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1102EUR$1,250USD£954GBP
- Report
- February 2025
- 144 Pages
Global
From €2645EUR$2,999USD£2,290GBP
- Report
- September 2025
- 287 Pages
Global
From €5159EUR$5,850USD£4,466GBP

Rituximab is a monoclonal antibody used to treat a variety of immune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and non-Hodgkin's lymphoma. It works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituximab is administered intravenously and is often used in combination with other drugs.
Rituximab is a relatively new drug, having been approved by the US Food and Drug Administration in 1997. Since then, it has become a popular treatment for immune disorders, due to its effectiveness and relatively low side effects. It is also used off-label to treat a variety of other conditions, such as multiple sclerosis and vasculitis.
The market for rituximab is highly competitive, with several major pharmaceutical companies producing the drug. These include Roche, Merck, Pfizer, and Biogen. Additionally, there are several generic versions of the drug available, produced by companies such as Sandoz and Teva Pharmaceuticals. Show Less Read more